Clinical Trials Browser

Phase 2 × OTHER × Immune-related Adverse Events × Clear all

NCT04375228 2026-02-06

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Phase 2 Active not recruiting

Other solid neoplasm

Immune-related Adverse Events